As reported by the World Health Organization, cancer continues to rank as a leading cause of death around the world. Recent studies have shown that immune checkpoint therapy is effective in a variety of advanced solid tumors and is becoming a hotspot for research into antitumor drugs. The development of immune checkpoint therapies targeting PD-L1 and PD-1 has resulted in significant improvements for various cancers. However, some kinds of cancer were regarded as immune-quiescent tumor, which means only a small proportion of patients would benefit from immunotherapy in addition to a high rate of severe adverse events. Therefore, developing new strategy to target the tumor microenvironment factors is important for cancer immunotherapy.

This topic is centered around all aspects of the immunotherapies targeting the tumor microenvironment of different cancers, including but not limited to immune checkpoint therapy, cancer related stroma cells, exhausted immune T cells, and immunotherapeutic drug delivery systems.

Potential topics to be covered:

• Novel immune cells or molecules in the cancer microenvironment

• Mechanism of immune escape in cancer

• Tumor microenvironment and cancer stem cells

• Strategies to overcome immunotherapy resistance in cancer

• New strategies to enhance immunotherapy effects

• Personalized immunotherapy for cancer

• Biomarkers for immunotherapy prediction

• Lipid metabolism in immunotherapy

• Exosomes in the cancer microenvironment

• Immunotherapeutic drug delivery systems

Keywords: Tumor microenvironment, cancer immunotherapy, PD-L1, immune escape, biomarker, multi-omics analysis